Published in J Oncol on July 17, 2012
Pheochromocytoma/Paraganglioma: Review of perioperative management of blood pressure and update on genetic mutations associated with pheochromocytoma. J Clin Hypertens (Greenwich) (2013) 1.19
Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families. Fam Cancer (2014) 0.88
Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nat Commun (2015) 0.87
Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted? J Am Coll Surg (2013) 0.86
Malignant extra-adrenal pancreatic paraganglioma: case report and literature review. BMC Cancer (2013) 0.83
Non-functioning Aortocaval Paraganglioma Masquerading as Celiac Lymphnodal Metastasis. Eurasian J Med (2014) 0.81
Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. Endocr Pathol (2017) 0.80
Malignant paraganglioma of the rectum: the first case report and a review of the literature. World J Gastroenterol (2013) 0.80
Two-stage bilateral laparoscopic adrenalectomy for large pheochromocytomas. Wideochir Inne Tech Maloinwazyjne (2014) 0.79
Mutation screening in a Norwegian cohort with pheochromocytoma. Fam Cancer (2013) 0.78
Phenotype of SDHB mutation carriers in the Netherlands. Fam Cancer (2014) 0.78
Malignant paraganglioma in children treated with embolization prior to surgical excision. World J Surg Oncol (2016) 0.75
Multiple nodal locoregional recurrence of pheochromocytoma. Int J Surg Case Rep (2015) 0.75
An unusual case of asymptomatic non-urothelial bladder tumour. Int J Surg Case Rep (2016) 0.75
Risk Stratification in Paragangliomas with PASS (Pheochromocytoma of the Adrenal Gland Scaled Score) and Immunohistochemical Markers. J Clin Diagn Res (2016) 0.75
Complete Remission in Metastatic Pheochromocytoma Treated with Extensive Surgery. Cureus (2016) 0.75
Pheochromocytoma in Urologic Practice. Eur Urol Focus (2016) 0.75
Multiple endocrine neoplasia similar to human subtype 2A in a dog: Medullary thyroid carcinoma, bilateral pheochromocytoma and parathyroid adenoma. Open Vet J (2016) 0.75
Adrenal imaging (Part 2): Medullary and secondary adrenal lesions. Indian J Endocrinol Metab (2015) 0.75
Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (1993) 11.95
Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med (1999) 11.27
Phaeochromocytoma. Lancet (2005) 8.73
Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science (2000) 8.64
Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med (2002) 6.94
The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell (1990) 4.84
Biochemical diagnosis of pheochromocytoma: which test is best? JAMA (2002) 4.84
Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet (2001) 4.71
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol (2008) 4.66
Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet (2000) 4.55
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol (2008) 3.85
SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science (2009) 3.72
Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene (2006) 3.51
The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A (2005) 3.49
Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today (2007) 3.36
Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab (2007) 3.25
Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol (1990) 3.22
Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab (2001) 3.19
SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet (2010) 3.07
A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet (2005) 2.85
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol (2006) 2.80
Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med (1993) 2.61
Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol (2007) 2.60
Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol (2002) 2.51
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther (2004) 2.32
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet (2011) 2.29
Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res (2003) 2.29
Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2007) 2.25
Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet (2010) 2.23
Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer (2006) 2.11
The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer (2007) 2.10
TORC1 is essential for NF1-associated malignancies. Curr Biol (2007) 2.08
Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab (2003) 2.08
High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab (2006) 2.04
Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet (1994) 2.04
Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab (2004) 2.00
Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res (2009) 1.96
Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.. Radiology (2002) 1.96
Pheochromocytoma: an imaging chameleon. Radiographics (2004) 1.84
The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS One (2009) 1.75
National Cancer Data Base report on malignant paragangliomas of the head and neck. Cancer (2002) 1.71
Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med (2001) 1.71
The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther (2003) 1.65
Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab (2007) 1.60
Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer (2011) 1.59
Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer (2008) 1.54
Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab (2009) 1.53
Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci (2006) 1.52
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med (2005) 1.51
Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery (2008) 1.50
Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev (1994) 1.48
Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach. Cancer Treat Rev (2010) 1.42
The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest (1997) 1.39
Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol (1999) 1.38
Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab (2008) 1.37
Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med (1988) 1.37
The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer (2006) 1.34
Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol (2003) 1.25
Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol (2002) 1.24
Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med (1996) 1.19
Changing paradigms in the treatment of malignant pheochromocytoma. Cancer Control (2011) 1.18
Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann N Y Acad Sci (2006) 1.15
Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab (2008) 1.14
Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med (1984) 1.11
MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer (2010) 1.11
Octreotide scintigraphy for the detection of paragangliomas. Otolaryngol Head Neck Surg (2000) 1.09
Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging (2008) 1.08
Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus? Ann N Y Acad Sci (2006) 1.07
Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies. Endocr Pathol (2012) 1.05
Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab (1998) 1.05
Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials. Clin Cancer Res (2004) 1.04
Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res (2009) 1.04
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer (2005) 1.00
VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery (2002) 0.98
Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment. Hypertension (2000) 0.97
Activation of HIF-prolyl hydroxylases by R59949, an inhibitor of the diacylglycerol kinase. J Biol Chem (2005) 0.96
Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [(123)I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nucl Med Commun (2006) 0.93
Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours. Endocr Regul (2001) 0.93
Signaling through Ras is essential for ret oncogene-induced cell differentiation in PC12 cells. J Biol Chem (2000) 0.93
VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. APMIS (2003) 0.93
Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma. J Clin Endocrinol Metab (2003) 0.93
Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma. Jpn J Clin Oncol (2009) 0.92
Dopamine-secreting pheochromocytomas: in search of a syndrome. World J Surg (2005) 0.92
Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas. Life Sci (2004) 0.91
Expression of the transcription factor snail and its target gene twist are associated with malignancy in pheochromocytomas. Ann Surg Oncol (2009) 0.88
Rapid degradation of hypoxia-inducible factor-1alpha by KRH102053, a new activator of prolyl hydroxylase 2. Br J Pharmacol (2008) 0.88
The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur J Endocrinol (2002) 0.87
Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate. J Clin Oncol (2008) 0.86
Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline. Ann Oncol (2003) 0.85
Phaeochromocytoma with normal urinary catecholamines: the potential value of urinary free metadrenalines. Ann Clin Biochem (2002) 0.84
Pheochromocytomas: detection with 11C hydroxyephedrine PET. Radiology (2004) 0.84
Hepatic ablation for neuroendocrine tumor metastases. J Surg Oncol (2009) 0.84
Expression of neuropeptides and other neuroendocrine markers in human phaeochromocytomas. Neuropeptides (1999) 0.83
Chromogranin A and the alpha-subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma. Br J Cancer (2001) 0.82
Retracted HSP90 is a key for telomerase activation and malignant transition in pheochromocytoma. Endocrine (2003) 0.82
[Distinction between benign and malignant pheochromocytomas]. Zhonghua Bing Li Xue Za Zhi (2004) 0.81
Expression and processing of the neuroendocrine protein secretogranin II in benign and malignant pheochromocytomas. Ann N Y Acad Sci (2006) 0.80
Identification and characterization of the gene for neurofibromatosis type 1. Curr Opin Genet Dev (1991) 0.80
Phaeochromocytoma. Lancet (2005) 8.73
Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med (2007) 6.58
Biochemical diagnosis of pheochromocytoma: which test is best? JAMA (2002) 4.84
Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension (2006) 4.20
A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol (2006) 3.74
Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab (2007) 3.25
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol (2009) 3.05
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet (2011) 2.29
Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem (2011) 2.24
A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes (2002) 2.15
Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney Int (2012) 1.77
Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab (2009) 1.53
Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem (2005) 1.52
Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer (2011) 1.49
Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer (2009) 1.48
Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism. Hypertension (2009) 1.45
Phaeochromocytoma, new genes and screening strategies. Clin Endocrinol (Oxf) (2006) 1.41
Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab (2008) 1.38
Identification of a locus for maturity-onset diabetes of the young on chromosome 8p23. Diabetes (2004) 1.34
Nuclear poly(ADP-ribose) polymerase-1 rapidly triggers mitochondrial dysfunction. J Biol Chem (2005) 1.33
Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool. J Biol Chem (2010) 1.27
Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA (2010) 1.22
MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res (2012) 1.22
Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer (2010) 1.21
Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension (2007) 1.13
The +276 G/T single nucleotide polymorphism of the adiponectin gene is associated with coronary artery disease in type 2 diabetic patients. Diabetes Care (2004) 1.12
Gene expression profiling of benign and malignant pheochromocytoma. Ann N Y Acad Sci (2006) 1.08
A variation in 3' UTR of hPTP1B increases specific gene expression and associates with insulin resistance. Am J Hum Genet (2002) 1.05
Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum Mol Genet (2013) 1.05
Poly(ADP-ribose) catabolism triggers AMP-dependent mitochondrial energy failure. J Biol Chem (2009) 1.03
Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab (2007) 1.02
Functional study in a yeast model of a novel succinate dehydrogenase subunit B gene germline missense mutation (C191Y) diagnosed in a patient affected by a glomus tumor. Hum Mol Genet (2009) 1.01
Poly(ADP-ribose) polymerase-1 is a nuclear epigenetic regulator of mitochondrial DNA repair and transcription. Mol Pharmacol (2011) 1.00
Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency. J Clin Endocrinol Metab (2014) 0.97
Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing's syndrome: a European multicentric study. J Clin Endocrinol Metab (2014) 0.97
Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab (2004) 0.97
Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens (2007) 0.96
The reticulin algorithm for adrenocortical tumor diagnosis: a multicentric validation study on 245 unpublished cases. Am J Surg Pathol (2013) 0.96
Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. Endocr Relat Cancer (2012) 0.96
Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling. PPAR Res (2008) 0.95
Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. J Clin Endocrinol Metab (2010) 0.92
Tumor necrosis factor-alpha exerts pro-myogenic action in C2C12 myoblasts via sphingosine kinase/S1P2 signaling. FEBS Lett (2007) 0.91
Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma. Am J Physiol Endocrinol Metab (2008) 0.91
TGFbeta protects mesoangioblasts from apoptosis via sphingosine kinase-1 regulation. Cell Signal (2008) 0.90
A role for calcium in Bcl-2 action? Biochimie (2002) 0.90
Elevated serum interferon-gamma-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines. J Clin Endocrinol Metab (2005) 0.89
Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab (2012) 0.89
Expression of the novel adrenocorticotropin-responsive gene selective Alzheimer's disease indicator-1 in the normal adrenal cortex and in adrenocortical adenomas and carcinomas. J Clin Endocrinol Metab (2004) 0.89
Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. Eur J Endocrinol (2005) 0.88
Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model. Endocr Relat Cancer (2010) 0.87
A case of hyponatremia caused by central hypocortisolism. Nat Clin Pract Endocrinol Metab (2007) 0.86
Uncommon clinical presentations of pheochromocytoma and paraganglioma in two different patients affected by two distinct novel VHL germline mutations. Clin Endocrinol (Oxf) (2007) 0.84
Sphingosine 1-phosphate inhibits cell migration in C2C12 myoblasts. Biochim Biophys Acta (2006) 0.84
Adrenal incidentaloma: the influence of a decision-making algorithm on the short-term outcome of laparoscopy. J Laparoendosc Adv Surg Tech A (2005) 0.83
Detection of circulating tumor cells in patients with adrenocortical carcinoma: a monocentric preliminary study. J Clin Endocrinol Metab (2013) 0.83
Yeast model for evaluating the pathogenic significance of SDHB, SDHC and SDHD mutations in PHEO-PGL syndrome. Hum Mol Genet (2012) 0.82
Integrative genetic, epigenetic and pathological analysis of paraganglioma reveals complex dysregulation of NOTCH signaling. Acta Neuropathol (2013) 0.81
H-RAS mutations are restricted to sporadic pheochromocytomas lacking specific clinical or pathological features: data from a multi-institutional series. J Clin Endocrinol Metab (2014) 0.81
Pitfalls in genetic analysis of pheochromocytomas/paragangliomas-case report. J Clin Endocrinol Metab (2014) 0.80
Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells. Endocr Relat Cancer (2013) 0.80
Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X. Int J Cancer (2014) 0.80
Pheochromocytoma in rats with multiple endocrine neoplasia (MENX) shares gene expression patterns with human pheochromocytoma. Proc Natl Acad Sci U S A (2010) 0.80
Handgrip-induced airway dilation in asthmatic patients with bronchoconstriction induced by MCh inhalation. J Appl Physiol (1985) (2002) 0.79
Xenograft models for preclinical drug testing: implications for adrenocortical cancer. Mol Cell Endocrinol (2011) 0.79
SPECT semiquantitative analysis of adrenocortical (131)I-6 beta iodomethyl-norcholesterol uptake to discriminate subclinical and preclinical functioning adrenal incidentaloma. J Nucl Med (2003) 0.79
Dissecting the origin of inducible brown fat in adult humans through a novel adipose stem cell model from adipose tissue surrounding pheochromocytoma. J Clin Endocrinol Metab (2014) 0.79
Seladin-1 expression is regulated by promoter methylation in adrenal cancer. BMC Cancer (2010) 0.78
Succinate dehydrogenase subunit B mutations modify human neuroblastoma cell metabolism and proliferation. Horm Cancer (2014) 0.77
Mapping of human autoantibody epitopes on aromatic L-amino acid decarboxylase. J Clin Endocrinol Metab (2007) 0.77
Role of the PPAR-γ system in normal and tumoral pituitary corticotropic cells and adrenal cells. Neuroendocrinology (2010) 0.77
Low sensitivity of glucagon provocative testing for diagnosis of pheochromocytoma. J Clin Endocrinol Metab (2009) 0.76
Genetic-clinical profile of subjects with apparently sporadic extra-adrenal paragangliomas. Front Endocrinol (Lausanne) (2012) 0.75